 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- ||| LBT-3627 / Longevity Biotech
Enrollment open: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - Aug 6, 2024
P1, N=64, Recruiting, Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
Not yet recruiting --> Recruiting
- | LBT-3627 / Longevity Biotech
New P1 trial: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - Jun 19, 2024
P1, N=64, Not yet recruiting, Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
- ||||||||| LBT-3627 / Longevity Biotech
Biomarker, Trial termination: Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - Apr 18, 2024
P=N/A, N=99, Terminated, Sponsor: Longevity Biotech
Not yet recruiting --> Recruiting Unknown status --> Terminated; COVID-19
- | LBT-3627 / Longevity Biotech
Journal: A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease. (Pubmed Central) - Oct 18, 2019
Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration...Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.
- || LBT-3627 / Longevity Biotech
Biomarker, Enrollment status: Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - May 22, 2019
P=N/A, N=134, Recruiting, Sponsor: Longevity Biotech
The data underscore an important role of immunity in PD pathogenesis. Enrolling by invitation --> Recruiting